Related references
Note: Only part of the references are listed.Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis
Angelo Sangiovanni et al.
JOURNAL OF HEPATOLOGY (2020)
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
Giuseppe Cabibbo et al.
JOURNAL OF HEPATOLOGY (2019)
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores
George N. Ioannou et al.
GASTROENTEROLOGY (2019)
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection
Elisabetta Degasperi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?
Yasuhiko Nakao et al.
JOURNAL OF HEPATOLOGY (2018)
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression
Roberta D'Ambrosio et al.
LIVER INTERNATIONAL (2018)
Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis
Sujan Ravi et al.
GASTROENTEROLOGY (2017)
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
Fasiha Kanwal et al.
GASTROENTEROLOGY (2017)
Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B
Hidenori Toyoda et al.
JOURNAL OF HEPATOLOGY (2017)
Global Cancer Incidence and Mortality Rates and Trends-An Update
Lindsey A. Torre et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis
A. Majumdar et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade
Hidenori Toyoda et al.
BRITISH JOURNAL OF CANCER (2016)
Changes in Patient Backgrounds May Increase the Incidence of HCC After SVR in the Era of IFN-Free Therapy for HCV
Hidenori Toyoda et al.
HEPATOLOGY (2016)
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
Fabio Conti et al.
JOURNAL OF HEPATOLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis
Soo Aleman et al.
CLINICAL INFECTIOUS DISEASES (2013)
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
Khayriyyah Mohd Hanafiah et al.
HEPATOLOGY (2013)
Radiofrequency ablation in the treatment of small hepatocellular carcinomas: Comparison of the radiofrequency effect with and without chemoembolization
M Kitamoto et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2003)
A model to predict survival in patients with end-stage liver disease
PS Kamath et al.
HEPATOLOGY (2001)
Share Paper
